COVID-19 UPDATE: U. Chicago Remdesivir study points to Treatment > Vaccine and 'game-changer'? Cases --> steady progress. More thoughts on Strategy "way forward"

COVID-19 remains a global crisis and we realize that many people need to keep up with COVID-19 developments, particularly since we are moving into the more critical stage ("restart economy"), so feel free to share our commentary to anyone who has interest.This evening, the most significant development comes from the Healthcare side as the University of Chicago's Phase 3 trial of Gilead's Remdesivir shows promise (link --> U Chicago Phase 3 trial update).  Remdesivir has been talked about for some time so we can understand if many wonder why this has any significance -- but the fact is, S&P 500 futures are up 100 points (+ ~3.5%).Policymakers have pointed to "vaccine" as the key development, and with vaccines 6-12-18 months away, the outlook for re-opening the economy is quite grim if a vaccine is key.  But if COVID-19 spread is 10-20X greater than reported, more like 20%-30% in NYC, not 1%-2% as "tested," then vaccines are less important than treatment.  This is something we mentioned in several of our comments -- that treatment > vaccine.  Think of it this way, a vaccine means the entire USA needs to be vaccinated and if 1% have side effects (just assumption, not a fact), then this would be worse arguably than catching COVID.  On the other hand, a treatment mea...

Unlock this article with a FREE 30-Day Trial!

An FSI Pro, or FSI Macro subscription is required in order to access this content.

*Free trial available only on a monthly plan

More from the author

Disclosures (show)

Get invaluable analysis of the market and stocks. Cancel at any time. Start Free Trial

Articles Read 2/2

🎁 Unlock 1 extra article by joining our Community!

You’ve reached your limit of 2 free monthly articles. Please enter your email to unlock 1 more articles.

Already have an account? Sign In

Don't Miss Out
First Month Free